ABGX-

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Michael Gallo, et al.

Application No.

09/375,924 Confirmation No.: 57

Filed:

August 17, 1999

For:

GENERATION OF MODIFIED MOLECULES WITH

INCREASED SERUM HALF-LIVES

Examiner

Marianne DeBrino, Ph.D.

Group

1644

Palo Alto, CA January 4, 2002

Hon. Commissioner for Patents Box AF c/o P. O. Box 2327

Arlington, Virginia 22202

Sir:

Responsive to the final Office Action mailed <u>July 5</u>, <u>2001</u>, applicants submit the following amendments and remarks. Applicants petition concurrently herewith under 37 C.F.R. § 1.136 for a three (3) month extension of time, extending time to respond to and including <u>January 5</u>, <u>2002</u>. Pursuant to 37 C.F.R. § 1.7(a), time to respond is extended to and including <u>January 7</u>, <u>2002</u>.

AMENDMENT AND RESPONSE UNDER 37 C.F.R. § 1.116

Applicants file concurrently herewith:

(1) Notice of appeal, with fee as specified under 37 C.F.R. § 1.17(b).

01/15/2002 CCHAU1 00000021 09375924

03 FC:117

920.00 OP

- (2) Supplemental Information Disclosure Statement, with fee as specified under 37 C.F.R. § 1.17(p), Form PTO-1149 in duplicate, and one copy of each listed reference;
- (3) Copy of original Information Disclosure Statement, copy of original Form PTO-1449 in duplicate, and copies of 148 listed references as first mailed to the PTO on May 15, 2000;
- (4) Copy of the Response to Notice to Comply With the Sequence Listing Requirements, containing a statement that the substitute paper copy and substitute computer readable form (CRF) of the sequence listing are the same and include no new matter, first mailed to the PTO on April 16, 2001;
- (5) Copy of the substitute paper copy of the Sequence Listing first mailed to the PTO on April 16, 2001;
- (6) Copy of the substitute CRF of the Sequence Listing first mailed to the PTO on April 16, 2001;
- (7) Appendix A containing copies of O.I.P.E.-stamped return postcards;
- (8) Appendix B containing copy of photocopying invoice;
- (9) Appendix C containing Table 4-2, "Properties and biological activities of classes and subclasses of human serum immunoglobulins," from Goldsby, R.A., et al., Immunology, 4th Ed. (2000), W.H. Freeman and Co., New York;
- (10) Appendix D containing West, A.P., et al., "Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor," Biochemistry, 39:9698-9708 (2000);
- (11) Appendix E containing Medesan, C., et al., "Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1," J. Immunol. (1997), 158:2211-2217;